| Literature DB >> 35670859 |
Abu Bakar Hafeez Bhatti1,2, Wajih Naqvi3, Nazish Ali3, Nusrat Yar Khan3, Haseeb Haider Zia3, Belqees Yawar Faiz4, Abid Ilyas5, Atif Rana4, Nasir Ayub Khan6.
Abstract
PURPOSE: Textbook outcome (TO) is a composite measure of outcome and provides superior assessment of quality of care after surgery. TO after major living donor hepatectomy (MLDH) has not been assessed. The objective of this study was to determine the rate of TO and its associated factors, after MLDH.Entities:
Keywords: Donor morbidity; Donor mortality; Future liver remnant; Post-hepatectomy liver failure; Right hepatectomy
Year: 2022 PMID: 35670859 PMCID: PMC9171097 DOI: 10.1007/s00423-022-02578-6
Source DB: PubMed Journal: Langenbecks Arch Surg ISSN: 1435-2443 Impact factor: 2.895
Fig. 1Modifications in donor operative pathway implemented in January 2019
Fig. 2Distribution of textbook outcome by its definition. Values are 714 (69.9%) for TO, 904 (88.5%) for ICU ≤ 2 days, 900 (88.1%) for hospital stay ≤ 10 days, 1014 (99.2%) for no liver failure, 908 (88.8%) for no 30-day major complications, 1004 (98.2%) for no 30-day re-admission, 990 (96.9%) for no peri-operative blood transfusion
Fig. 3Post-donation 30-day complications (grade 3 and above), others (n = 4) included (re-exploration = 2, tube thoracostomy for pneumothrorax = 1, re-intubation for adult respiratory distress syndrome = 1)
Baseline characteristics of donors who underwent a major living donor hepatectomy between April 2012 and July 2021
| Variable | Patients no. (%) | ||
|---|---|---|---|
| Textbook outcome ( −) | Textbook outcome ( +) | ||
| Total | 308 (30.1) | 714 (69.9) | NA |
| Sex | 0.393 | ||
| Male | 203 (29.3) | 490 (70.7) | |
| Female | 165 (31.9) | 164 (68.1) | |
| Age, years, median (IQR) | 26 (21.2–34) | 25 (25–32) | 0.942 |
| Body mass index, median (IQR), Kg/m2 | 24.3 (21.9–26.8) | 24 (21.1–26.9) | 0.225 |
| Liver attenuation index, median (IQR) | 12 (7–16) | 12 (8–16) | 0.169 |
| Donation era | 0.001 | ||
| Early ( | 249 (33) | 506 (67) | |
| Late ( | 59 (22.1) | 208 (77.9) | |
| Graft type | 0.171 | ||
| Right lobe | 297 (30.6) | 674 (69.4) | |
| Left lobe | 11 (21.6) | 40 (78.4) | |
| MHV included in right lobe grafts ( | 0.379 | ||
| Complete/partial | 62 (28.2) | 158 (71.8) | |
| Not taken | 235 (31.3) | 516 (68.7) | |
| HBV-core-antibody positive | 0.231 | ||
| Yes | 51 (26.6) | 141 (73.4) | |
| No | 257 (31) | 573 (69) | |
| Future liver remnant, % | 0.043 | ||
| < 35 | 185 (32.7) | 380 (67.3) | |
| ≥ 35 | 123 (26.9) | 334 (73.1) | |
| Portal venous anatomy | 0.860 | ||
| Variant | 37 (30.8) | 83 (69.2) | |
| Standard | 271 (30) | 631 (70) | |
| Biliary anatomy | 0.040 | ||
| Variant | 69 (36.3) | 121 (63.7) | |
| Standard | 239 (28.7) | 593 (71.3) | |
Multivariate analysis of factors associated failure to achieve a textbook outcome
| Variable | Groups | Odds ratio | Odds ratio | ||
|---|---|---|---|---|---|
| Type of lobe | Right | 1.4 (0.7–2.5) | 0.255 | - | - |
| Left | 1 | - | - | ||
| Future liver remnant | < 35 | 1.21 (0.96–1.5) | 0.09 | 1.2 (0.97–1.5) | 0.077 |
| ≥ 35 | 1 | - | - | ||
| MHV with graft | Taken | 1.05 (0.91–1.2) | 0.463 | - | - |
| Not taken | 1 | - | - | ||
| HBV-core-antibody | Positive | 1.16 (0.86–1.5) | 0.317 | - | - |
| Negative | 1 | - | - | ||
| Donation era | Early | 1.49 (1.1–1.9) | 0.006 | 1.4 (1.1–1.9) | 0.006 |
| Late | 1 | - | - | ||
| Portal anatomy | Variant | 1.02 (0.72–1.4) | 0.882 | - | - |
| Standard | 1 | - | - | ||
| Biliary anatomy | Variant | 1.26 (0.96–1.6) | 0.086 | 1.2 (0.9–1.5) | 0.18 |
| Standard | 1 | - | - |
Grade 3 and above complications and individual outcome measures in early (April 2012–Decemeber 2018) and late donation era (January 2019–July 2021)
| Variable | Early donation era ( | Later era | |
|---|---|---|---|
| Biliary complications ( | 16 (2.1) | 4 (1.5) | 0.61 |
| Abdominal collections ( | 58 (7.7) | 11 (4.1) | 0.046 |
| Pleural effusions ( | 34 (4.5) | 10 (3.7) | 0.6 |
| Wound infections ( | 8 (1.1) | 1 (0.4) | 0.035 |
| Pneumonia ( | 9 (1.2) | 0 | 0.12 |
| Hospital stay > 10 days ( | 99 (13.1) | 23 (8.6) | 0.05 |
| ICU stay > 2 days ( | 106 (14) | 12 (4.5) | < 0.001 |
| Readmission ( | 9 (1.2) | 9 (3.4) | 0.02 |
| Blood transfusion ( | 26 (3.4) | 5 (1.9) | 0.1 |
| Liver failure ( | 7 (0.9) | 1 (0.4) | 0.6 |
Comparison of individual outcome measures based on ICU stay
| Variable | Patients no. (%) | ||
|---|---|---|---|
| ICU stay ≤ 2 days ( | ICU stay > 2 days ( | ||
| Major complications ( | 95 (10.5) | 19 (16.1) | 0.07 |
| Blood transfusion ( | 24 (2.7) | 8 (6.7) | 0.003 |
| Re-admission ( | 16 (1.8) | 2 (1.7) | > 0.99 |
| Liver failure ( | 6 (0.7) | 2 (1.7) | 0.23 |
| Hospital stay > 10 days ( | 96 (10.6) | 26 (22) | < 0.001 |
Fig. 4a Precut cholangiogram (after liver transection) with bulldog clamp applied near the confluence (yellow arrow) to identify point of division of RHD. b Completion cholangiogram with RHD stump (yellow arrow) after graft procurement to prevent biliary complications in the donor. c A modified right lobe graft with MHV exposure, segment 5 (V5) and segment 8 (V8) veins will be ligated and used for reconstruction